Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

66.23USD
29 Jul 2016
Change (% chg)

$1.51 (+2.33%)
Prev Close
$64.72
Open
$65.27
Day's High
$66.40
Day's Low
$65.15
Volume
10,525,016
Avg. Vol
8,206,651
52-wk High
$71.51
52-wk Low
$45.45

Latest Key Developments (Source: Significant Developments)

AbbVie Inc and Boehringer Ingelheim announce collaboration on promising immunology compounds
Monday, 7 Mar 2016 08:00am EST 

AbbVie Inc:Abbvie and boehringer ingelheim announce global collaboration on promising immunology compounds.Says AbbVie will make an initial upfront payment of US$ 595 million.Says boehringer ingelheim will retain responsibility for further development of bi 655064.Says AbbVie may elect to advance the program after completion of certain undisclosed clinical achievements.Boehringer ingelheim will be eligible to receive milestone payments on net sales, the terms of which are not disclosed.Says AbbVie will be solely responsible for commercialization of bi 655066.  Full Article

AbbVie Inc - UK cost agency rejects leukaemia drug from J&J and AbbVie - Reuters
Tuesday, 1 Mar 2016 02:01pm EST 

AbbVie Inc:A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain's healthcare cost-effectiveness agency NICE, which said it could not be confident the medicine represented an effective use of resources - RTRS.Imbruvica has a list price of 55,954.50 pounds ($78,000) a year, although it is being offered at an undisclosed discount to the National Health Service by European supplier Janssen, a unit of Johnson & Johnson.Janssen said on Wednesday it was "extremely disappointed" by the draft recommendation from the National Institute for Health and Care Excellence (NICE), which contrasted with decisions in 48 other countries to fund the medicine.Imbruvica is the first in a new class of cancer drugs known as Burton's tyrosine kinase inhibitors. Excitement over its prospects prompted AbbVie ABBV.N to buy Pharmacyclics, which developed the medicine with J&J, for $21 billion last year.  Full Article

AbbVie Inc receives EMA orphan drug designation for investigational compound venetoclax for treatment of acute myeloid leukemia
Friday, 26 Feb 2016 06:01am EST 

AbbVie Inc:Receives EMA orphan drug designation for investigational compound venetoclax for treatment of acute myeloid leukemia.Says Venetoclax is being developed by AbbVie in partnership with Genentech and Roche.  Full Article

Myriad Genetics expands strategic research collaboration with AbbVie
Tuesday, 23 Feb 2016 07:05am EST 

Myriad Genetics:Expands strategic research collaboration with AbbVie.Other terms of the deal were not disclosed.Under the terms of the agreement, AbbVie will use Myriad's CDx portfolio - myChoice HRD.  Full Article

AbbVie Inc declares quarterly dividend
Thursday, 18 Feb 2016 11:05am EST 

AbbVie Inc:Declared a quarterly cash dividend of $0.57 per share.Cash dividend is payable May 16 to stockholders of record date as on April 15.  Full Article

AbbVie Inc posts positive phase 3 results from endometriosis drug study
Wednesday, 10 Feb 2016 06:56am EST 

AbbVie Inc:Announces positive top-line results from second phase 3 study investigating elagolix in patients with endometriosis.Says new drug application for endometriosis anticipated in 2017.Says study meets co-primary efficacy endpoints and full results will be presented at a medical conference in 2016.Says results show elagolix reduces endometriosis-associated pain (menstrual and non-menstrual pelvic pain) compared to placebo.  Full Article

AbbVie Inc's IMBRUVICA Phase 3 RAY Data Show Reductions in Disease Progression versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients
Monday, 7 Dec 2015 08:30am EST 

AbbVie:Announced results from Phase 3 RAY (MCL3001) trial, which showed IMBRUVICAsignificantly prolonged progression-free survival and improved overall response rates in patients with relapsed or refractory mantle cell lymphoma (MCL), compared with temsirolimus.IMBRUVICA was associated with a 57% reduction in the risk of progression or death with a median follow-up of 20 months.  Full Article

AbbVie Inc's VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Monday, 28 Sep 2015 02:00am EDT 

AbbVie Inc:Abbvie's viekirax® (ombitasvir/paritaprevir/ritonavir tablets) receives approval in Japan for the treatment of genotype 1 chronic hepatitis c.New interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan, genotype 1 chronic hepatitis c.  Full Article

AbbVie to advance Once-Daily ABT-494 to phase 3 in Rheumatoid Arthritis by Year-End
Friday, 25 Sep 2015 07:13am EDT 

AbbVie Inc:Says to opt-out of collaboration with Galapagos on filgotinib.Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.Per the terms of the agreement with Galapagos, all rights to filgotinib will revert solely to Galapagos.  Full Article

AbbVie Inc's ABT-494 meets primary endpoint in two phase 2 studies in Rheumatoid Arthritis
Friday, 25 Sep 2015 07:08am EDT 

AbbVie Inc:Announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.Clinical trials, BALANCE-I and BALANCE-II, achieved ACR20 at week 12 across all dose levels, except the lowest dose in BALANCE-II.Intends to move rapidly to Phase 3 studies of ABT-494 by the end of 2015 with a once-daily formulation.Says the primary endpoint of both studies was ACR20 response at week 12.In the TNF-inadequate responder population, ACR20 responses up to 73 percent and ACR50 responses up to 44 percent.In the MTX-inadequate responder population, ACR20 responses up to 82 percent and ACR50 responses up to 50 percent.Says overall rates of discontinuation and serious adverse events were <5% and <3%, respectively, across both studies.  Full Article

Photo

Drugmaker AbbVie bumps up profit forecast on strong Humira sales

AbbVie Inc posted higher-than-expected quarterly profit and revenue, driven by demand for its flagship drug Humira, and raised its earnings forecast for the year.